Dapagliflozin DPPIV Inhibitor add-on Study

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Bristol-Myers Squibb
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

• Patients with type 2 diabetes

• Patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these

• Patients will be screened by a blood test and only those who need additional therapy can be enrolled

Exclusion Criteria:

• Patients with type 1 diabetes

• Patients with very poorly controlled diabetes

• Any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study